

**Supporting Information: Appendix belonging to**

**Population immunity to pre-Omicron and Omicron SARS-CoV-2 variants in US states and counties through December 1, 2021**

**Authors:** Fayette Klaassen, Melanie H. Chitwood, Ted Cohen, Virginia E. Pitzer, Marcus Russi, Nicole A. Swartwood, Joshua A. Salomon and Nicolas A. Menzies

**Correspondence to:** [fklaassen@hsph.harvard.edu](mailto:fklaassen@hsph.harvard.edu)

This file contains:

**SI Methods.**

**Table S1.**

**Table S2.**

**Table S3.**

**Table S4.**

**Figure S1.**

**Figure S2.**

**Figure S3.**

**Figure S4.**

**Figure S5.**

**Figure S6.**

## SI Methods

### Imputation of cases and deaths data for Nebraska counties

The time-series of cases and deaths data are truncated for counties in Nebraska after June 30, 2021, due to non-reporting of cases and deaths data at the county level. To produce estimates for Nebraska we imputed cases and deaths for each county based on state-level cases and deaths, assuming each county experienced the same proportional changes in cumulative cases and deaths as reported at the state level.

### Imputation and temporal disaggregation of vaccination data

We extracted estimates from a repository reporting county-level vaccination coverage based on CDC vaccination data, adjusted for known biases and incompleteness in several states<sup>1,2</sup>. These estimates include weekly values for the number of county residents having received at least one COVID-19 vaccine dose (*First dose*) and the number of residents having completed an FDA-approved vaccine sequence (*Fully vaccinated*). We imputed missing *First dose* estimates using the observed *Fully vaccinated* data, and smoothed weekly data to create a daily time-series.

We imputed data for 2,006 counties in the weekly vaccination data (*First dose*) (minimum missing weeks: 1, 567 counties, maximum missing weeks: 35, 8 counties). The states with the highest percentage of counties with missing data are Nebraska and South Dakota. After the temporal disaggregation of the weekly time series to daily data, a remaining 57 counties had missing data at the end of the time-series (minimum missing days: 8, maximum missing days: 211).

We used a three-step process to render a daily timeseries from the (irregular) weekly timeseries. First, we used linear interpolation to impute missing *First dose* and *Fully vaccinated* data on a weekly (7-day) interval from January 10th, 2021. Second, we disaggregated the weekly time series to the daily level, using a second order smoothness constraint. This method fits a smooth line that always passes the observation on the first day of the week and increases in the following days<sup>3</sup>. Third, we imputed the remaining missing data of at the end of the time series using the following approach.

We imputed the missing data of *First dose* at time  $X$  using the fraction of people who get fully vaccinated. We assume there is an average lag of  $Y$  days between *First dose* and *Fully vaccinated*. For a single-dose vaccine (Johnson, 8% of all fully vaccinated individuals), the status *Fully vaccinated* is achieved on the same day as the *First dose*. For Moderna (37.3% of all fully vaccinated individuals), the recommended time between the first and second dose is four weeks (28 days). For Pfizer-BioNTech (54.6%), the recommended time is three weeks (21 days)<sup>4,5</sup>. The weighted average of time until fully vaccinated is 22 days.

For each time point, we computed the fraction fully vaccinated. The missing values of *First dose* were calculated from the imputed values and had to meet the constraint that at any time, the total number *First dose* must be smaller than the total population size. We further constrain the time series to be monotonically increasing.

Children under 12 years old were not eligible for COVID-19 vaccination in the time period of analysis. We constrained the fraction of the full population with a *First dose* to never exceed the fraction of the full population of 12 years and older. For example, Santa Cruz, Arizona, reports 99% of its population has received a *First dose*, while only 81% of the population is 12 years and older. In this case, we constrain the fraction vaccinated to be 81%.

### Logistic regression rendering state specific odds ratios of vaccination given infection status

We used a logistic regression model to estimate the association between self-reported vaccination status and prior COVID-19 diagnosis. The regression model included fixed effects for week and state. We also included state-level random coefficients for prior COVID-19 diagnosis, to allow for state-level differences in the overlap between vaccination and prior infection. Below is the full regression model, where  $X_{(i)}$  is a model matrix for the specified variable. We used a binomial likelihood to model the number people with a self-reported vaccination status ( $n$ ) out of the total ( $N$ ).

$$\begin{aligned} \text{logit}(\theta) &= \mathbf{b}_0 + X_{\text{week}} \mathbf{b}_{\text{week}} + X_{\text{state}} \mathbf{b}_{\text{state}} + X_{\text{state} \times \text{covid}} (\mathbf{b}_{\text{covid}} + \mathbf{g}_{\text{r.e.}}) \\ \mathcal{L}(\theta|N, n) &= \theta^n (1 - \theta)^{N-n} \\ g_{\text{r.e.}} &\sim \mathcal{N}(0, \sigma) \\ \sigma &\sim U(0, \infty) \end{aligned}$$

### Derivation of joint probability from odds ratio

We have estimates of the probability of ever being infected and (adjusted) data of the probability of ever being vaccinated. In addition, we have a specified a data-driven prior distribution on the odds ratio of vaccination for those with a prior diagnosis versus those without a prior diagnosis. We want to compute the probability of being immune (the probability of ever being vaccinated and/or infected).

Following the rules of probability and our definition of immunity, we can compute the probability of being immune as a function of the probability of vaccinated, infected, and the conditional probability of being vaccinated given prior infection.

$$\begin{aligned} p_{\text{immune}} &= p_{\text{vac} \cup \text{inf}} \\ &= p_{\text{vac}} + p_{\text{inf}} - p_{\text{vac} \cap \text{inf}} \\ &= p_{\text{vac}} + p_{\text{inf}} - p_{\text{vac}} p_{\text{vac} | \text{inf}} \\ &= p_{\text{vac}} + p_{\text{inf}} - p_{\text{vac}} \frac{O_{\text{vac} | \text{inf}}}{1 + O_{\text{vac} | \text{inf}}} \end{aligned}$$

To compute the probability of being immune, we need an expression for the unknown  $O_{\text{vac} | \text{inf}}$ . Making use of the fact that:

$$\begin{aligned} \frac{O_{\text{vac} | \text{inf}}}{O_{\text{vac} | \text{not inf}}} &= OR \\ O_{\text{vac} | \text{inf}} &= OR O_{\text{vac} | \text{not inf}} \end{aligned}$$

we can express  $p_{\text{vac}}$  as a function of  $p_{\text{inf}}$ ,  $OR$  and  $O_{\text{vac} | \text{not inf}}$

$$\begin{aligned} p_{\text{vac}} &= p_{\text{inf}} p_{\text{vac} | \text{inf}} + p_{\text{not inf}} p_{\text{vac} | \text{not inf}} \\ &= p_{\text{inf}} \frac{O_{\text{vac} | \text{inf}}}{1 + O_{\text{vac} | \text{inf}}} + p_{\text{not inf}} \frac{O_{\text{vac} | \text{not inf}}}{1 + O_{\text{vac} | \text{not inf}}} \\ &= p_{\text{inf}} \frac{OR O_{\text{vac} | \text{not inf}}}{1 + OR O_{\text{vac} | \text{not inf}}} + (1 - p_{\text{inf}}) \frac{O_{\text{vac} | \text{not inf}}}{1 + O_{\text{vac} | \text{not inf}}} \\ &= \frac{p_{\text{inf}} OR O_{\text{vac} | \text{not inf}}}{1 + OR O_{\text{vac} | \text{not inf}}} + \frac{O_{\text{vac} | \text{not inf}} - p_{\text{inf}} O_{\text{vac} | \text{not inf}}}{1 + O_{\text{vac} | \text{not inf}}} \end{aligned}$$

For readability, let us define short hands for the above terms.

$$\begin{aligned} p_{\text{vac}} &= v \\ p_{\text{inf}} &= i \\ O_{\text{vac} | \text{not inf}} &= d \text{ (for odds)} \\ OR &= r \text{ (for odds ratio)} \end{aligned}$$

Using the new labels, rearranging the terms, and equating to zero renders a quadratic equation of  $d$  ( $O_{\text{vac}|\text{not inf}}$ ):

$$\begin{aligned} v &= \frac{ird}{1+rd} + \frac{d-id}{1+d} \\ 0 &= v(1+rd)(1+d) - ird(1+d) - (d-id)(1+rd) \\ &= v + vrd + vd + vrd^2 - ird - ird^2 - d + id - rd^2 + ird^2 \\ &= (vr-r)d^2 + (vr+v-ir+i-1)d + v \end{aligned}$$

Making the following substitutions,

$$\begin{aligned} (vr-r) &= a \\ (vr+v-ir+i-1) &= b \\ v &= c \end{aligned}$$

allows us to solve the quadratic formula, rendering a solution for  $O_{\text{vac}|\text{not inf}}$ , which allows us to compute the joint probability of being vaccinated and infected, and finally the probability of being immune.

$$\begin{aligned} \frac{-b \pm \sqrt{b^2 + 4ac}}{2a} &= d = O_{\text{vac}|\text{not inf}} \\ O_{\text{vac}|\text{inf}} &= O_{\text{vac}|\text{not inf}} \text{ OR} \\ p_{\text{vac}|\text{inf}} &= \frac{O_{\text{vac}|\text{inf}}}{1 + O_{\text{vac}|\text{inf}}} \\ p_{\text{vac} \cap \text{inf}} &= p_{\text{vac}} p_{\text{vac}|\text{inf}} \end{aligned}$$

## Waning functions

We propose four simplistic functions of waning of immunity (Figure S1), under three scenarios: a baseline scenario, used in the analyses in the manuscript, and an additional optimistic and pessimistic scenario (dotted lines in Figure S1) for sensitivity analyses.

Baseline scenario:

- Protection against infection conferred by vaccination or natural infection is 80% for the first two months after natural infection or vaccination, then declines to 50% in month 4, and then declines more slowly over the next five months, such that the protection nine months after infection or vaccination is 25% and constant thereafter.
- Protection against infection conferred by the combination of vaccination and natural infection is 90% and does not decline.
- Protection against severe outcomes conferred by vaccination or natural infection is 95% for the first six months after infection or complete vaccination, and then declines by 10 percent points every six months.
- Protection against severe outcomes conferred by the combination of natural infection and vaccination is 95% and does not decline.

Optimistic scenario:

- Protection against infection conferred by vaccination or natural infection is 90% for the first two months after natural infection or vaccination, then declines to 75% over the next two months, and then declines further over the next five months, such that the protection nine months after infection or vaccination is 50% and constant thereafter.
- Protection against infection conferred by the combination of vaccination and natural infection is 95% and does not decline.
- Protection against severe outcomes conferred by vaccination or natural infection is 100% for the first six months after the infection or complete vaccination, and then declines by 5 percent points every six months.
- Protection against severe outcomes accrued by the combination of natural infection and vaccination is 100% and does not decline.

Pessimistic scenario:

- Protection against infection conferred by vaccination or natural infection is 75% for the first two months after natural infection or vaccination, then declines to 45% over the next two months, and then declines further over the next five months, such that the protection nine months after infection or vaccination is 20% and constant thereafter.
- Protection against infection conferred by the combination of vaccination and natural infection is 80% for the first six months after being previously infected and vaccinated, and then declines by 10 percent points every six months.
- Protection against severe outcomes conferred by vaccination or natural infection is 100% for the first six months after the infection or complete vaccination, and then declines by 20 percent points every six months.
- Protection against severe outcomes conferred by the combination of natural infection and vaccination is 90% for the first six months after being previously infected and vaccinated, and then declines by 10 percent points every six months.

### **Validation of Household Pulse Survey data**

We fit a logistic regression model on the Axios-Ipsos Coronavirus Survey data<sup>6</sup>, similar to the logistic regression we used for the Household Pulse Survey data, that was used in the main analyses. The Axios-Ipsos survey data does not have state-specific estimates, rendering a simplified regression equation:

$$\begin{aligned}\text{logit}(\theta) &= b_0 + X_{\text{week}} \mathbf{b}_{\text{week}} + X_{\text{covid}} b_{\text{covid}} \\ \mathcal{L}(\theta|W, w) &= \theta^w (1 - \theta)^{W-w} \\ b_{(\cdot)} &\sim \mathcal{N}(0, 1000)\end{aligned}$$

**Table S1:** Means and standard deviations of the log-normal prior distributions for odds ratio of vaccination given infection status for each US state.

State	Odds ratio	Lower bound 95% CrI	Upper bound 95% CrI
Florida	0.400	0.361	0.444
Michigan	0.455	0.390	0.529
Oregon	0.469	0.397	0.555
Washington	0.47	0.401	0.551
North Carolina	0.475	0.424	0.532
Pennsylvania	0.484	0.428	0.547
Alaska	0.488	0.407	0.586
Illinois	0.495	0.441	0.557
New Mexico	0.501	0.403	0.623
Maryland	0.503	0.425	0.596
New Jersey	0.504	0.439	0.578
Arizona	0.505	0.444	0.574
New York	0.505	0.46	0.556
Vermont	0.507	0.406	0.633
Hawaii	0.508	0.417	0.618
Delaware	0.511	0.421	0.621
Indiana	0.512	0.449	0.584
West Virginia	0.512	0.431	0.608
Connecticut	0.516	0.44	0.605
North Dakota	0.516	0.431	0.617
Idaho	0.516	0.434	0.614
Colorado	0.516	0.447	0.596
Nevada	0.517	0.431	0.621
Massachusetts	0.518	0.441	0.607
Ohio	0.518	0.466	0.575
Wyoming	0.519	0.427	0.631
Rhode Island	0.519	0.432	0.625
Kansas	0.521	0.441	0.616
Minnesota	0.523	0.446	0.612
Maine	0.525	0.442	0.623
Mississippi	0.526	0.445	0.621
District of Columbia	0.53	0.438	0.641
Georgia	0.53	0.472	0.595
Tennessee	0.532	0.457	0.62
New Hampshire	0.534	0.435	0.656

Montana	0.535	0.439	0.651
Oklahoma	0.535	0.456	0.627
Missouri	0.535	0.467	0.614
Utah	0.536	0.451	0.637
Nebraska	0.537	0.435	0.663
Virginia	0.538	0.459	0.629
South Dakota	0.538	0.444	0.653
Arkansas	0.541	0.456	0.643
South Carolina	0.541	0.464	0.632
California	0.545	0.502	0.591
Iowa	0.554	0.472	0.652
Wisconsin	0.555	0.483	0.638
Alabama	0.56	0.484	0.649
Louisiana	0.567	0.487	0.659
Kentucky	0.569	0.486	0.665
Texas	0.581	0.532	0.634

**Table S2:** Relative risk of infection and severe outcomes (Omicron versus pre-Omicron) for those with protection.

	RR of infection	RR of infection (boosted)	RR of severe disease	RR of severe disease (boosted)
High immune escape	.1	.4	.7	.8
Medium immune escape	.3	.6	.8	.9
Low immune escape	.5	.8	.9	.95



**Table S3:** Effective protection outcomes for each US state on December 1, 2021 under base-case, pessimistic and optimistic scenarios.

State	<i>Effective protection against infection; base-case scenario (pessimistic; optimistic); no immune escape</i>	<i>Effective protection against infection with Omicron; pessimistic waning + high immune escape scenario (95%CrI)</i>	<i>Effective protection against infection with Omicron; base-case waning + medium immune escape scenario (95%CrI)</i>	<i>Effective protection against infection with Omicron; optimistic waning + low immune escape scenario (95%CrI)</i>
Alabama	52.8% (46.2-63.7)	11.5% (11.2-11.9)	20.7% (19.9-21.7)	27.4% (26.2-28.6)
Alaska	57.7% (50.8-66.5)	14% (13.6-14.4)	24.2% (23.2-25.4)	31.4% (29.8-33.1)
Arizona	58.8% (51.2-68.5)	12.4% (12.1-12.7)	22.9% (22.1-23.8)	30.1% (29-31.2)
Arkansas	50.5% (44.1-61.2)	11.9% (11.6-12.4)	20.6% (19.8-21.9)	26.8% (25.4-28.5)
California	55.3% (47.9-65.4)	12.4% (12-12.8)	22.1% (20.9-23.8)	28.7% (27-31.1)
Colorado	63.2% (55-71.8)	15% (14.8-15.4)	26.4% (25.3-27.8)	33.9% (32.3-35.9)
Connecticut	58.8% (50.8-69.1)	13.7% (13.5-14.2)	24.1% (23-25.9)	31% (29.3-33.6)
Delaware	56.8% (49.4-66.6)	13.2% (12.9-13.6)	23.2% (22.2-24.7)	30% (28.4-32.2)
District of Columbia	55.7% (48.3-66.4)	11.4% (11.1-11.8)	21.2% (20-23)	28% (26.3-30.7)
Florida	60.5% (53-70.1)	12.6% (12.3-13.1)	23.5% (22.3-24.8)	31.2% (29.5-33.1)
Georgia	51.8% (45.2-62.7)	11.1% (10.8-11.6)	20.2% (19.2-21.2)	26.6% (25.3-28)
Hawaii	46.4% (40.2-60.4)	10.1% (9.9-10.5)	17.8% (16.9-19.6)	23.4% (22.1-26.2)

Idaho	54.7% (48.1-64.2)	13.8% (13.5-14.2)	23.4% (22.6-24.3)	30.1% (28.8-31.4)
Illinois	52.6% (45.3-62.9)	13.1% (12.8-13.6)	22.2% (21.1-23.9)	28.2% (26.6-30.6)
Indiana	47.9% (41.6-58.3)	11.6% (11.3-12.2)	19.8% (18.8-21.4)	25.5% (24-27.7)
Iowa	53% (45.8-62.4)	14.7% (14.5-15.2)	23.9% (23.1-25.2)	29.8% (28.5-31.7)
Kansas	52.6% (45.7-62.5)	12.5% (12.2-12.9)	21.7% (20.7-23.1)	27.9% (26.5-30)
Kentucky	55.1% (48.2-64.8)	13.3% (13-13.7)	23% (22.1-24.1)	29.7% (28.3-31.2)
Louisiana	51.1% (44.4-62)	11.6% (11.3-12.1)	20.5% (19.6-21.7)	26.7% (25.3-28.3)
Maine	55.5% (48.3-66.2)	14.6% (14.4-15)	24.2% (23.3-25.9)	30.7% (29.2-33.3)
Maryland	55.1% (47.8-65.4)	13.4% (13.2-13.9)	23.1% (22-24.8)	29.5% (28-32.1)
Massachusetts	57.4% (49.6-67.7)	13.3% (13-13.8)	23.4% (22.3-25.2)	30.1% (28.4-32.7)
Michigan	53.3% (46.3-63.2)	14% (13.7-14.5)	23.2% (22.4-24.5)	29.4% (28.1-31.1)
Minnesota	54.2% (46.9-63.3)	15.1% (14.8-15.5)	24.5% (23.7-25.9)	30.6% (29.2-32.7)
Mississippi	50.8% (44.2-61.9)	11.2% (10.9-11.7)	20% (19.1-21.2)	26.2% (24.9-27.8)
Missouri	46.8% (40.6-57.2)	11.7% (11.4-12.3)	19.7% (18.8-21.3)	25.2% (23.8-27.5)
Montana	55.1% (48.1-64.4)	14.4% (14.1-14.9)	24.1% (23.2-25.2)	30.6% (29.3-32.2)

Nebraska	51.8% (45.2-61.3)	13.4% (13-14.1)	22.4% (21.1-24.3)	28.6% (26.4-31.4)
Nevada	55.4% (48.3-65.5)	11.7% (11.1-12.4)	21.5% (19.7-23.6)	28.4% (25.7-31.5)
New Hampshire	54.9% (48.6-67.3)	8.4% (8.1-8.9)	18.1% (16.9-20.1)	25.7% (23.9-28.7)
New Jersey	57.6% (49.8-67.4)	12.6% (12.3-13)	22.8% (21.6-24.5)	29.7% (27.9-32.1)
New Mexico	62.4% (54.4-71.1)	14.7% (14.5-15)	25.9% (25.2-26.7)	33.4% (32.4-34.4)
New York	57.8% (50.1-67.9)	11.1% (10.8-11.5)	21.4% (20.1-23.2)	28.6% (26.7-31)
North Carolina	46.2% (40.1-57.4)	9.4% (8.9-10.1)	17.3% (15.8-19.6)	23% (20.8-26.5)
North Dakota	53.2% (46-63.1)	13.6% (13.3-14)	22.8% (22.1-23.8)	28.9% (27.9-30.1)
Ohio	48.3% (41.8-58.2)	13% (12.7-13.7)	21.3% (20.3-23.2)	26.7% (25.2-29.6)
Oklahoma	57.8% (50.8-67.4)	12.3% (12-12.6)	22.6% (21.8-23.5)	29.9% (28.7-31.1)
Oregon	52.8% (46.2-63)	13.2% (13-13.8)	22.4% (21.3-24.5)	28.8% (26.9-32.1)
Pennsylvania	56.3% (49.1-66.8)	10.8% (10.4-11.2)	20.7% (19.4-22.6)	27.9% (26-30.6)
Rhode Island	61.2% (53.2-70.6)	14.3% (14-14.6)	25.2% (24.2-26.6)	32.5% (31-34.4)
South Carolina	51.9% (45.2-62.3)	12% (11.7-12.5)	21% (20-22.3)	27.3% (25.9-29.2)
South Dakota	55.4% (48.4-64.7)	13.1% (12.9-13.5)	22.9% (22.1-24.1)	29.6% (28.5-31.2)

Tennessee	51.7% (44.9-62.1)	12.7% (12.3-13.5)	21.6% (20.4-23.7)	27.8% (25.9-30.8)
Texas	54.4% (47.3-64.3)	11.5% (11.2-11.9)	21.1% (20.1-22.4)	27.8% (26.3-29.6)
Utah	49% (42.9-59)	11.2% (10.8-11.7)	19.7% (18.6-21)	25.8% (24.2-27.7)
Vermont	50.4% (43.6-59.2)	15.5% (15.4-15.9)	24.2% (23.5-25.7)	29.6% (28.4-32.1)
Virginia	50.1% (43.4-60.2)	12.6% (12.3-13.1)	21.2% (20.3-22.9)	27.1% (25.5-29.6)
Washington	50.9% (44.3-61.5)	12.8% (12.5-13.3)	21.6% (20.6-23.3)	27.6% (26-30.3)
West Virginia	41.6% (36.8-53.1)	7.3% (6.8-8)	14.4% (13.2-15.8)	20.1% (18.4-22)
Wisconsin	52.9% (45.7-62.4)	14.3% (14.1-14.9)	23.5% (22.7-25.3)	29.5% (28.1-32.1)
Wyoming	56.2% (49.4-66)	13.8% (13.3-14.7)	23.7% (22.1-25.8)	30.7% (28.2-33.8)

**Table S4:** Effective protection against severe disease for each US state on December 1, 2021 under base-case, pessimistic and optimistic scenarios.

State	<i>Effective protection</i> against severe disease; base-case scenario (pessimistic; optimistic); no immune escape	<i>Effective protection</i> against severe disease with Omicron; pessimistic waning + high immune escape scenario (95%CrI)	<i>Effective protection</i> against severe disease with Omicron; base-case waning + medium immune escape scenario (95%CrI)	<i>Effective protection</i> against severe disease with Omicron; optimistic waning + low immune escape scenario (95%CrI)
Alabama	74.1% (67.2-79.2)	57.3% (54.3-60.5)	61% (57.9-64.3)	61.3% (58.5-64.2)
Alaska	73.9% (68.2-78.5)	57.5% (54.9-60.5)	61.6% (58.8-64.8)	62.5% (59.5-65.7)
Arizona	77.3% (70.1-82.5)	59.7% (57.9-61.5)	63.7% (61.9-65.5)	64% (62.4-65.4)
Arkansas	71.5% (64.8-76.4)	55.5% (52.4-59.3)	59.1% (55.8-63)	59.2% (56-62.8)
California	75.3% (68.8-80.1)	58.1% (56.7-60)	62.2% (60.7-64.3)	62.8% (61.2-64.9)
Colorado	78.9% (72.6-83.6)	61.3% (60.6-62.2)	65.8% (64.9-66.7)	66.5% (65.6-67.6)
Connecticut	79.5% (72.8-84.4)	61.5% (61-62.3)	65.9% (65.3-66.8)	66.6% (65.9-67.6)
Delaware	75.8% (69.2-80.7)	58.8% (57.1-60.9)	62.8% (61-65.1)	63.2% (61.5-65.4)
District of Columbia	77.3% (70.7-82.3)	59.2% (58.4-60.5)	63.4% (62.5-64.8)	64.4% (63.5-65.8)
Florida	78.5% (72.3-83.3)	60.3% (58.8-62)	64.7% (63-66.5)	66% (64.3-67.7)
Georgia	73.4% (66.3-78.6)	56.7% (53.7-60.1)	60.3% (57.2-63.7)	60.4% (57.6-63.4)
Hawaii	77.3% (71-82.3)	59% (58.8-59.6)	63.2% (62.9-64)	64.5% (64-65.6)

Idaho	72.5% (66.3-77.2)	56.6% (53.3-60.4)	60.4% (57-64.3)	60.8% (57.4-64.5)
Illinois	73.3% (66.3-78.3)	57.2% (55.4-59.6)	60.9% (59.1-63.5)	60.7% (59-63.3)
Indiana	68.8% (62-73.7)	53.6% (50.6-57.7)	57% (53.8-61.3)	56.7% (53.7-60.8)
Iowa	71.4% (64.5-76.2)	56.3% (53.9-59.6)	60% (57.4-63.4)	59.4% (56.9-62.7)
Kansas	72.3% (65.8-77)	56.1% (53.7-59.1)	59.9% (57.4-63.1)	60.2% (57.7-63.3)
Kentucky	73.9% (67.7-78.6)	57.4% (54.6-60.7)	61.4% (58.4-64.8)	62% (59-65.2)
Louisiana	72% (64.8-77.3)	56% (53.1-59.4)	59.5% (56.5-62.8)	59.2% (56.5-62.1)
Maine	77.2% (71.1-82)	60.2% (59.3-61.7)	64.4% (63.4-66.2)	65.2% (64-67.3)
Maryland	75.8% (69.4-80.6)	58.8% (57.8-60.3)	62.9% (61.8-64.6)	63.5% (62.3-65.3)
Massachusetts	77.9% (71-82.9)	60.3% (59.3-61.7)	64.5% (63.4-66.1)	64.9% (63.8-66.5)
Michigan	72.6% (65.5-77.7)	57.1% (54.2-60.6)	60.7% (57.7-64.2)	60.2% (57.4-63.4)
Minnesota	71.9% (65.4-76.6)	56.7% (54.6-59.6)	60.4% (58.3-63.5)	60.2% (58-63.2)
Mississippi	72.4% (65.2-77.7)	56.1% (53.2-59.5)	59.6% (56.6-63.1)	59.4% (56.7-62.5)
Missouri	67.8% (61.4-72.5)	52.8% (49.7-57.3)	56.2% (52.9-60.9)	56.1% (52.9-60.7)
Montana	72.9% (66.6-77.7)	57.2% (54.3-60.7)	61% (57.9-64.7)	61.2% (58.1-64.8)

Nebraska	70.3% (63.8-75)	55.1% (51.1-59.6)	58.7% (54.4-63.4)	58.6% (54.3-63.4)
Nevada	75% (68.5-80)	57.8% (54.3-61.2)	61.7% (58-65.5)	62.4% (58.6-66.3)
New Hampshire	80.2% (74.8-84.9)	60% (59.5-60.9)	64.7% (64.1-65.7)	67.6% (67-68.7)
New Jersey	76.8% (69.8-81.8)	59.3% (58.2-60.7)	63.4% (62.2-64.9)	63.7% (62.6-65.2)
New Mexico	78.4% (71.8-83.3)	61% (59.6-62.4)	65.2% (63.8-66.6)	65.8% (64.5-66.9)
New York	77.4% (70.5-82.5)	59.2% (58.2-60.6)	63.4% (62.2-64.8)	64.1% (63-65.4)
North Carolina	69.4% (62.8-74.2)	53.3% (50-57.7)	56.7% (53.3-61.5)	57.1% (53.5-62.1)
North Dakota	72.6% (64.9-77.8)	57% (54.2-60.2)	60.5% (57.6-63.7)	59.6% (56.9-62.5)
Ohio	68.2% (61.5-72.9)	53.5% (50.6-58.3)	56.9% (53.8-62)	56.4% (53.3-61.6)
Oklahoma	76% (69.8-80.8)	58.5% (56.3-60.8)	62.7% (60.3-65.1)	63.7% (61.4-65.9)
Oregon	73.1% (67.4-77.7)	56.8% (55-59.7)	60.8% (58.8-64)	61.7% (59.5-65.3)
Pennsylvania	77.3% (70.9-82.2)	58.9% (57.8-60.4)	63.2% (62-64.9)	64.5% (63.2-66.2)
Rhode Island	78.7% (71.9-83.7)	61.1% (59.9-62.5)	65.3% (64.1-66.9)	65.8% (64.6-67.2)
South Carolina	72.2% (65.5-77.2)	56% (53.1-59.6)	59.7% (56.7-63.4)	59.8% (56.9-63.3)
South Dakota	73.3% (66.7-78.2)	57.1% (55-59.5)	60.9% (58.8-63.4)	61.1% (59.1-63.5)

Tennessee	72.3% (65.4-77.3)	56.4% (52.8-61.4)	60% (56.3-65.4)	59.8% (56.1-65.3)
Texas	73.6% (67-78.5)	56.8% (54.8-59.1)	60.6% (58.5-63)	61.1% (59.1-63.3)
Utah	68.8% (62.8-73.4)	53.2% (50-57.2)	56.8% (53.4-61)	57.4% (54-61.4)
Vermont	67.8% (62-72)	53.7% (51.7-57.4)	57.4% (55.2-61.4)	57.2% (54.8-61.6)
Virginia	70.7% (64.4-75.3)	55% (53-58.2)	58.7% (56.6-62.1)	59% (56.8-62.5)
Washington	72.3% (66.4-76.8)	56.1% (54.5-58.6)	60% (58.3-62.8)	60.8% (58.9-63.7)
West Virginia	65.4% (59.2-70.1)	49.8% (44.3-56.5)	53% (47.3-60)	53.6% (48.1-60.4)
Wisconsin	71.7% (65.1-76.4)	56.3% (54.2-59.9)	60.1% (57.8-63.8)	59.9% (57.5-63.8)
Wyoming	74.7% (68.3-79.5)	58.2% (53.6-63.3)	62.1% (57.2-67.5)	62.6% (57.4-68.2)



**Figure S1:** Assumed waning curves for protection against infection and severe disease, from natural infection and/or vaccination.

Footnote: Dashed lines indicate the optimistic and pessimistic scenario.

**Figure S2:** County-level estimates of the fraction of the population with *immunological exposure* at four time-points between December 31, 2020 and December 1, 2021.

**Figure S3:** County-level estimates of the fraction of the population with *effective protection* against infection on December 1, 2021, assuming no, low, medium, or high immune escape.

**Figure S4:** Contribution of prior infection and vaccination to the fraction of the population *immunologically exposed* for each US state over time.

Footnote: Purple: percent ever infected and not vaccinated. Green: percent vaccinated and not prior infected. Blended color: percent ever infected and vaccinated. Darker shades: received booster.

**Figure S5:** Contribution of effective protection from prior infection and vaccination or both to the total effective protection for each US state over time.

Footnote: Purple: effective protection from those infected and not vaccinated. Green: effective protection from those vaccinated and not prior infected. Blended color: effective protection from those infected and vaccinated. Darker shades: received booster.

**Figure S6:** Comparison of immunity estimates for each US state, with credible intervals, with blood donor estimates of immunity<sup>7</sup>.

Footnote: red lines indicate the blood donor estimates

## SI References

1. Tiu A, Susswein Z, Merritt A, Bansal S. Characterizing the spatiotemporal heterogeneity of the COVID-19 vaccination landscape. *MedRxiv*. 2021.
2. Merritt A, Tiu A, Bansal S. 2021. "Integrated US COVID-19 Vaccination Data." Harvard Dataverse, V1. <https://doi.org/10.7910/DVN/BFRIKI>.
3. Sax C, Steiner P. Temporal Disaggregation of Time Series. *The R Journal*. 2013;5(2):80-80. <https://doi.org/10.32614/rj-2013-028>.
4. Centers for Disease Control and Prevention. COVID data tracker. <https://covid.cdc.gov/covid-data-tracker>. Published 2020. Accessed October 22, 2021.
5. Centers for Disease Control and Prevention. Vaccines for COVID-19. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html>. Published 2021. Accessed October 22, 2021.
6. Ipsos. Axios-Ipsos Coronavirus Index, waves 34-48. Ann, Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], doi:10.3886/E144903V1
7. Jones JM, Stone M, Sulaeman H, et al. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021. *JAMA*. 2021. <https://doi.org/10.1001/jama.2021.15161>.